Good
Mostly Aligned
Patient Risk:
Low
Summary
The claims largely align with the label sections 14.1 (CV outcomes) and 14.2 (weight reduction) and reflect major trial findings (MACE reduction, long-term weight change, Trial counts). Several claims are unsupported or contradicted by the label (notably HbA1c outcomes in non-diabetics, specific cholelithiasis/pancreatitis incidence figures, and some long-term extension data). A subset of statements also reference data/extensions not clearly specified in the current label text. Overall, the claims show substantial alignment with the labeled content but include notable inaccuracies and unsupported assertions.
Category Scores
UseInSpecificPopulations
70
Accurate Statements
In the SELECT trial, Wegovy reduced risk of major adverse cardiovascular events by 20% over 39.8 months.
14.1: Hazard ratio for MACE 0.80 (0.72-0.90) indicating a 20% relative reduction.
Most data come from STEP trials (68-104 weeks).
14.2: STEP trials are the primary source of weight management data in obesity/overweight populations.
Most data come from SELECT trials (up to 4 years, n=17,604).
14.1: SELECT CV outcomes trial includes 17,604 randomized participants.
No trials exceed 4 years yet.
14.1 and 14.2 present data up to 4 years; no label data beyond 4 years are described.
Ongoing extensions track 5+ years.
Label content does not clearly describe 5+ year extensions; this claim is not explicitly supported by the sections provided.
Rodent signals prompted monitoring for thyroid C-cell tumor risk.
5.1 notes rodent thyroid C-cell tumor risk prompting monitoring.
Some GLP-1 analyses show bone fractures and decreased bone density.
6.1 includes fractures; bone density changes are discussed in the broader safety sections.
In SELECT over 4 years, Wegovy produced -9.5% weight change.
14.1 includes long-term weight data; label text references a -9.5% weight change in SELECT over 4 years.
In STEP 5 (2 years), Wegovy produced -15.2% weight change.
14.2 includes STEP 5 weight-change data; the -15.2% figure appears in the weight-change tables.
In STEP 5, lifestyle alone produced -2.6% weight change.
14.2 includes a lifestyle comparison showing weight change; the reported figure aligns with the trial data.
Unsupported Statements
Wegovy trials up to 2 years demonstrate sustained weight loss of 15-17% body weight.
Label data show substantial weight loss with STEP trials up to ~68 weeks and SELECT data at 4 years; explicit 15-17% sustained weight loss up to 2 years is not clearly stated in the label sections provided.
In the SELECT trial, 83% of participants maintained at least 10% weight loss after 4 years.
Label sections provided do not explicitly report an 83% maintenance rate at 10% weight loss in SELECT.
HbA1c reductions persist, dropping 1-1.5% in obese patients without diabetes.
Label data show HbA1c changes in diabetic populations; non-diabetic obesity trials show little or no HbA1c reduction reported in 14.2 weight-maintenance trials.
Weight regain occurs if Wegovy is discontinued; 5-10% within a year post-STEP.
Label does not provide a specific weight regain percentage after discontinuation in STEP; this figure is not described in the label sections provided.
Pancreatitis incidence is similar to placebo.
Label notes pancreatitis in Wegovy-treated patients with some cases observed; incidence is not described as similar to placebo in the provided sections.
No increased thyroid C-cell tumors in humans.
Label indicates unknown human relevance of rodent thyroid C-cell tumors; it does not state no increased risk in humans.
Wegovy-specific data show no clear signal of bone fractures or bone density loss over 2 years.
Label discusses bone-related adverse events (fractures) in trials; the claim of no clear signal over 2 years is not fully supported by the provided label data.
Chronic kidney effects are neutral or protective in SELECT subgroups.
Label states effects not significantly altered by renal function impairment but does not explicitly claim 'neutral or protective' within SELECT; interpretation is partial.
Pregnancy registry is ongoing.
Label sections include pregnancy exposure registry information; this is stated, so this could be considered supported, not unsupported. (If treated as unsupported, this entry would be incorrect.)
Contradictions
Low
AI Statement
Symptomatic cholelithiasis occurred in 4% of Wegovy participants over 2 years.
Label Reference
6.1 / 5.3
Low
AI Statement
Symptomatic cholelithiasis occurred in 2% of placebo participants over 2 years.
Label Reference
6.1 / 5.3
Low
AI Statement
Pancreatitis incidence is 0.1-0.2% with Wegovy.
Label Reference
6.1 / 5.2
Low
AI Statement
Pancreatitis incidence is similar to placebo.
Label Reference
6.1
Low
AI Statement
No increased thyroid C-cell tumors in humans.
Label Reference
5.1
Low
AI Statement
Wegovy-specific data show no clear signal of bone fractures or bone density loss over 2 years.
Label Reference
6.1
Low
AI Statement
In SELECT over 4 years, Wegovy produced -9.5% weight change.
Label Reference
14.1
Important Omissions
Explicit long-term extension data beyond 4 years are not clearly described in the provided label sections.
Importance:
Moderate
Detailed HbA1c outcomes in non-diabetic obese/overweight populations are not clearly presented in 14.2.
Importance:
Moderate
Exact weight-change figures beyond 4-year SELECT data (beyond -9.5%) are not exhaustively reported in the given sections.
Importance:
Moderate
Safety Assessment
Potential Patient Risk:
Low
Label supports known adverse events with relatively low incidence (e.g., cholelithiasis, pancreatitis) and common GI events, with no new safety signals beyond established warnings.
Regulatory Assessment
| On Label |
Yes |
| Off-label Discussion |
No |
| Promotes Unapproved Use |
No |
| Hallucination Risk |
Low |
Recommendation
Mostly Aligned
Primary Issue
Some claims are not explicitly supported or are contradicted by label data (e.g., specific HbA1c changes in non-diabetics, exact cholelithiasis/pancreatitis incidence figures, long-term extension data).
Suggested Improvement
Align extracted claims with explicit label data; avoid implying outcomes not clearly reported (e.g., 2–4 year exact weight-change figures without corresponding LSMean context); clearly distinguish data from STEP vs SELECT studies and ensure unit/case matches (percent vs percent change from baseline vs difference from placebo).